By Iulia Filip
The puzzle of cardiovascular (CV) risk reduction in people with HIV (PWH) is a hard one to solve in the absence of CV risk calculators and prevention strategies that are specifically designed for this population. However, findings from the phase 3 Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) may change how clinicians approach the use of prevention tools in low-risk individuals with HIV infection.
Read the full article here here.
